PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib

BACKGROUND: Lenvatinib, regorafenib and anti-programmed cell death protein-1 (PD-1) immunotherapy have shown promising clinical outcomes in patients with advanced hepatocellular carcinoma (HCC) after sorafenib failure, respectively. However, the combination of the two treatments has not been reporte...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yongkang, Fu, Shumin, Shang, Kai, Zeng, Jiayu, Mao, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513444/
https://www.ncbi.nlm.nih.gov/pubmed/36176403
http://dx.doi.org/10.3389/fonc.2022.958869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513444/
https://www.ncbi.nlm.nih.gov/pubmed/36176403
http://dx.doi.org/10.3389/fonc.2022.958869

Ejemplares similares